Published in Healthcare Mergers, Acquisitions and Ventures Week, April 16th, 2005
The trial will be a randomized, double-blind, active comparator controlled, parallel-group study and will seek to demonstrate similar efficacy of Colal-Pred to conventional oral prednisolone, but with a substantially improved side effect profile.
The trial will involve up to 670 patients who have moderate to severe ulcerative colitis. Patients will undergo 8 weeks of treatment and a 4-week follow-up period. In addition to the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Healthcare Mergers, Acquisitions and Ventures Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.